MedTrace Logo

Protein Electrophoresis as a Tool for Complications Prediction in COVID-19 Hospitalised Patients

NCT04414059 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-10-19

No results posted yet for this study

Summary

The inflammation is central in COVID-19 infections. Our aim is to evaluate the clinical value of measuring inflammation by using serum protein electrophoresis (SPE). SPE evaluation of inflammation should be able to predict outcome, follow up evolution or treatment efficacy in patients with coronavirus infection and thus anticipate their evolution to severe viral infection and allow an optimal clinical management. SPE inflammation diagnostics will be benchmarked with other diagnostics of inflammation, currently used more routinely.

Conditions

  • SARS-CoV 2
  • Hospitalisation-Associated Infection

Sponsors & Collaborators

  • Elsan

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-10
Primary Completion
2022-05-10
Completion
2022-09-10

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04414059 on ClinicalTrials.gov